Prospective Grant of Exclusive License: Use of Recombinant Yeast Expressing CEA for the Prevention and Treatment of Cancer, 8391-8392 [E7-3153]
Download as PDF
<![CDATA[
ycherry on PROD1PC64 with NOTICES
Federal Register / Vol. 72, No. 37 / Monday, February 26, 2007 / Notices
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Gertrude K. McFarland,
FAAN, RN, DNSC, Scientific Review
Administrator, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 3156, MSC 7770, Bethesda, MD
20892, (301) 435–1784, mcfarlag@csr.nih.gov.
Name of Committee: AIDS and Related
Research Integrated Review Group; AIDSassociated Opportunistic Infections and
Cancer Study Section.
Date: March 19, 2007.
Time: 8 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Watergate Hotel, 2650 Virginia
Avenue, NW., Washington, DC 20037.
Contact Person: Eduardo A. Montalvo,
PhD, Scientific Review Administrator, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5212,
MSC 7852, Bethesda, MD 20892, (301) 435–
1168, montalve@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Infectious
Diseases and Microbiology Fellowships.
Date: March 19–20, 2007.
Time: 8:30 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: St. Gregory Hotel, 2033 M Street,
NW., Washington, DC 20036.
Contact Person: John C. Pugh, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
MSC 7808, Bethesda, MD 20892, (301) 435–
2398, pughjohn@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Regulation
of Axonal Growth and Synaptic Plasticity.
Date: March 19, 2007.
Time: 11 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Lawrence Baizer, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4152,
MSC 7850, Bethesda, MD 20892, (301) 435–
1257, baizerl@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Neurogenesis and Stem Cells.
Date: March 19, 2007.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Joanne T. Fugii, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4184,
MSC 7850, Bethesda, MD 20892, (301) 435–
1178, fujiij@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–06–
389: Basic and Translational Research
VerDate Aug<31>2005
16:03 Feb 23, 2007
Jkt 211001
Opportunities in the Social Neuroscience of
Mental Health.
Date: March 20–21, 2007.
Time: 6 a.m. to 7 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Jane A. DoussardRoosevelt, PhD, Scientific Review
Administrator, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 3184, MSC 7848, Bethesda, MD
20892, (301) 435–4445,
doussarj@csr.nih.gobv.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–06–
473 Translational Research on the
Relationship of Anxiety and Depression
(R21).
Date: March 20–21, 2007.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Maribeth Champouxs,
PhD, Scientific Review Administrator, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3146,
MSC 7759, Bethesda, MD 20892, 301–594–
3163, champoum@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Neural System.
Date: March 20, 2007.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Bernard F. Driscoll, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5184,
MSC 7844, Bethesda, MD 20892, (301) 435–
1242, driscolb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Heart
Failure.
Date: March 20, 2007.
Time: 2:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Maqsood A. Wani, PhD,
DVM, Scientific Review Administrator,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 2114, MSC 7814, Bethesda, MD 20892,
301–435–2270, wanimaqs@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Social Sciences.
Date: March 21, 2007.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
8391
Contact Person: Ann Hardy, DRPH,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3158,
MSC 7770, Bethesda, MD 20892, (301) 435–
0695, hardyan@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cognition.
Date: March 21, 2007.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Bernard F. Driscoll, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5184,
MSC 7844, Bethesda, MD 20892, (301) 435–
1242, driscolb@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; BGES
Special Emphasis Panel Study Section–HOP
E 02 M.
Date: March 21, 2007.
Time: 4 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Karin F. Helmers, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3166,
MSC 7770, Bethesda, MD 20892, (301) 435–
1017, helmersk@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 15, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–835 Filed 2–23–07; 8:45am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Use of Recombinant Yeast
Expressing CEA for the Prevention and
Treatment of Cancer
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
Part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
E:\FR\FM\26FEN1.SGM
26FEN1
ycherry on PROD1PC64 with NOTICES
8392
Federal Register / Vol. 72, No. 37 / Monday, February 26, 2007 / Notices
patent license to practice the inventions
embodied in U.S. Patent 6,756,038 and
PCT Application Serial No. PCT/US98/
19794 and foreign equivalents thereof,
entitled ‘‘Agonist and Antagonist
Peptides of Carcinoembryonic Antigen
(CEA)’’ (E–099–1996/0) and U.S. Patent
6,969,582 and PCT Application Serial
No. PCT/US99/26866 and foreign
equivalents thereof, entitled ‘‘A
Recombinant Vector Expressing
Multiple Costimulatory Molecules and
Uses Thereof’’ (E–256–1998/0), to
GlobeImmune Inc., which is located in
Louisville, Colorado. The patent rights
in these inventions have been assigned
to the United States of America. The
prospective exclusive license territory
may be worldwide and the field of use
may be limited to the use recombinant
Saccharomyces cerevisiae expressing
CEA for the prevention and treatment of
cancer.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before April
27, 2007 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Michelle A. Booden,
PhD., Technology Licensing Specialist,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 451–
7337; Facsimile: (301) 402–0220; E-mail:
boodenm@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
technology describes the composition
and use of nucleic acid sequences that
encode agonist and one antagonist
peptide variants of the human
carcinoembryonic antigen (CEA)
peptide, including but not limited to
CAP–1. CEA is an antigen, which is
expressed on the surface of various
types of cancer cells. It is capable of
stimulating a specific cytolytic T cell
response, as is CAP–1, which is a highly
immunogenic epitope of CEA.
Therefore, CAP–1 agonists which are
capable of eliciting a CEA-specific
cytolytic T cell response, such as those
identified by the inventors, may
represent potential immunogens for use
as therapeutic agents or vaccines against
various cancers, and possibly also for
use against autoimmune diseases. In
fact, at least one of the agonist peptides
appears to be more immunogenic than
the native CAP–1 peptide. CAP–1
antagonists which are capable of
reducing or eliminating this T cell
response, such as the antagonist peptide
variant identified by the inventors, may
VerDate Aug<31>2005
16:03 Feb 23, 2007
Jkt 211001
represent potential agents for use
against autoimmune responses to CEA
or to agonist peptide variants thereof.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR Part 404.7. The
prospective exclusive license may be
granted unless within sixty (60) days
from the date of this published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR Part 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: February 16, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–3153 Filed 2–23–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences 2008–2012 Strategic Plan
Notice with request for
comments.
ACTION:
SUMMARY: NIGMS is initiating a strategic
planning process that will culminate in
the NIGMS Strategic Plan for 2008–
2012. To assist with this process,
NIGMS requests input from scientists,
scientific organizations, and other
interested parties. The goal of this
strategic planning process is to identify
Institute priorities and guide decisionmaking over the next five years.
Information about NIGMS can be found
at https://www.nigms.nih.gov/.
In order to ensure full
consideration, responses must be
submitted by 12 midnight EDT on
March 20, 2007.
DATES:
Interested individuals and
organizations should submit their
responses to https://www.nigms.nih.gov/
About/StrategicPlan/Input.htm.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Background
The mission of the National Institute
of General Medical Sciences (NIGMS) is
to support basic research whose results
lay the foundation for the diagnosis,
treatment, and prevention of disease.
NIGMS-funded researchers seek to
answer important questions in fields
such as cell biology, biophysics,
genetics, developmental biology,
pharmacology, physiology,
biochemistry, chemistry, bioinformatics,
and computational biology, and in
selected cross-cutting clinical areas that
affect multiple organ systems. NIGMS
also provides leadership in promoting
the diversity of the scientific workforce
and in training the next generation of
scientists to assure the vitality and
continued productivity of basic
research.
NIGMS has embarked on a strategic
planning process to identify Institute
priorities to guide decision-making over
the next five years. To assure the
broadest possible input, NIGMS is
inviting the scientists, scientific
organizations, and other interested
parties to respond electronically to a
series of questions, listed below.
• What factors should NIGMS
consider in deciding how to set its
priorities with respect to new and
existing areas of support?
• What factors should NIGMS
consider in deciding how to set its
priorities with respect to research
training?
• What new or emerging areas,
approaches, or technologies in basic
biomedical research should NIGMS
pursue?
• As part of its efforts to maintain a
balanced research portfolio, how can
NIGMS best encourage and support
research that is highly innovative and/
or risky?
• Are there areas of current NIGMS
research activity that should receive less
emphasis?
• How can NIGMS enhance its
communication with the scientific
community and the public?
• How can NIGMS more effectively
promote and encourage greater diversity
in the biomedical research workforce?
You may also submit other comments
relevant to NIGMS that are not
specifically addressed in these
questions.
Responses will be limited to
approximately 500 words per question.
All information provided will be
processed and analyzed with strict
anonymity.
Contact Person: Judith H. Greenberg,
PhD., National Institute of General
Medical Sciences, National Institutes of
E:\FR\FM\26FEN1.SGM
26FEN1
]]>Agencies
[Federal Register Volume 72, Number 37 (Monday, February 26, 2007)]
[Notices]
[Pages 8391-8392]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-3153]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Use of Recombinant Yeast
Expressing CEA for the Prevention and Treatment of Cancer
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR Part 404.7(a)(1)(i), that the National Institutes of Health,
Department of Health and Human Services, is contemplating the grant of
an exclusive
[[Page 8392]]
patent license to practice the inventions embodied in U.S. Patent
6,756,038 and PCT Application Serial No. PCT/US98/19794 and foreign
equivalents thereof, entitled ``Agonist and Antagonist Peptides of
Carcinoembryonic Antigen (CEA)'' (E-099-1996/0) and U.S. Patent
6,969,582 and PCT Application Serial No. PCT/US99/26866 and foreign
equivalents thereof, entitled ``A Recombinant Vector Expressing
Multiple Costimulatory Molecules and Uses Thereof'' (E-256-1998/0), to
GlobeImmune Inc., which is located in Louisville, Colorado. The patent
rights in these inventions have been assigned to the United States of
America. The prospective exclusive license territory may be worldwide
and the field of use may be limited to the use recombinant
Saccharomyces cerevisiae expressing CEA for the prevention and
treatment of cancer.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
April 27, 2007 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Michelle A. Booden, PhD., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; Telephone: (301) 451-7337; Facsimile: (301) 402-0220; E-
mail: boodenm@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The technology describes the composition and
use of nucleic acid sequences that encode agonist and one antagonist
peptide variants of the human carcinoembryonic antigen (CEA) peptide,
including but not limited to CAP-1. CEA is an antigen, which is
expressed on the surface of various types of cancer cells. It is
capable of stimulating a specific cytolytic T cell response, as is CAP-
1, which is a highly immunogenic epitope of CEA. Therefore, CAP-1
agonists which are capable of eliciting a CEA-specific cytolytic T cell
response, such as those identified by the inventors, may represent
potential immunogens for use as therapeutic agents or vaccines against
various cancers, and possibly also for use against autoimmune diseases.
In fact, at least one of the agonist peptides appears to be more
immunogenic than the native CAP-1 peptide. CAP-1 antagonists which are
capable of reducing or eliminating this T cell response, such as the
antagonist peptide variant identified by the inventors, may represent
potential agents for use against autoimmune responses to CEA or to
agonist peptide variants thereof.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part
404.7. The prospective exclusive license may be granted unless within
sixty (60) days from the date of this published notice, the NIH
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR Part 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: February 16, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-3153 Filed 2-23-07; 8:45 am]
BILLING CODE 4140-01-P
